大塚ホールディングス（4578） – Notice Regarding Revisions of Consolidated Results Forecast for FY2021

January 27, 2022 For Immediate Release Company name Representative Code number Inquiries Otsuka Holdings Co., Ltd. Tatsuo Higuchi President and Representative Director, CEO 4578 First Section , Tokyo Stock Exchange Yuji Kogure Director, Investor Relations Department Notice Regarding Revisions of Consolidated Results Forecast for FY2021 It is hereby notified that Otsuka Holdings Co., Ltd. (the “Company”), in light of recent developments of its business results, has revised its consolidated financial forecasts for FY2021, previously announced on November 12, 2021. 1. Revision of the consolidated financial forecasts for FY2021 Revenue Profit attributable to owners of the Company Million yen Million yen Million yen Million yen Million yen Million yen Profit for the year Profit before tax Operating profit Business profit Basic earnings per share Yen 151,733 189,988 198,582 216,887 1,422,826 165,000 129,000 (36,000) (21.8%) 210,000 163,000 (47,000) (22.4%) 200,000 157,000 (43,000) (21.5%) 203,000 154,000 (49,000) (24.1%) 161,000 125,000 (36,000) (22.4%) 1,480,000 1,498,000 18,000 1.2% Previous forecast (A) Revised forecast (B) Amount of change (B-A) Change (%) (Reference) Consolidated results for FY2020 2. Reasons for the revision In the fourth quarter of FY2021, the cost of sales is expected to exceed approximately 10 billion yen from the recent forecast due to one-time factors, such as approximately 8 billion yen of additional costs related to the co-promotion agreement of TREMFYA, and the impact of exchange rate fluctuations incurred by the elimination of unrealized gains on inventories in the pharmaceutical business. Meanwhile, aggressive upfront investments in new brands for FY2022 of Pharmavite, which is currently increasing sales steadily, and in launching new pharmaceutical products have been made, and research and development expenses have increased due to the execution of the collaboration and license agreement for joint development and commercialization with Sumitomo Dainippon Pharma Co., Ltd. and Sunovion Pharmaceuticals Inc. As a result, business profit is expected to be lower than the recent forecast. Operating profit is expected to be lower than the recent forecast due to the changes in the fair value of contingent consideration for centanafadine and an impairment loss on fixed assets. The forecast for profit before taxes, net profit for the year and profit attributable to owners of the company have been revised downward in line with the above-mentioned revision of the operating profit. 148,137 Please note that the results for FY 2021 (fiscal year ending December 31, 2021) and the forecasts for FY 2022 (fiscal year ending December 31, 2022) will be announced on February 10, 2022. 296.84 230.46 273.15 Note: The above forecasts are based on information available and certain assumptions that the Company deems reasonable at the time of the announcement. Actual operating results may differ from these projections due to various factors. -2-